Portal de Periódicos da CAPES

Oral etoposide in the treatment of hormone-refractory prostate cancer

1994; Wiley; Volume: 74; Issue: 1 Linguagem: Inglês

10.1002/1097-0142(19940701)74

1097-0142

Maha Hussain, Kenneth J. Pienta, Bruce G. Redman, Glenn Cummings, Lawrence E. Flaherty,

Lung Cancer Research Studies

CancerVolume 74, Issue 1 p. 100-103 Original ArticleFree Access Oral etoposide in the treatment of hormone-refractory prostate cancer Maha H. Hussain M.D., Corresponding Author Maha H. Hussain M.D. Hematology/Oncology, VA Medical Center, Allen Park, Michigan, Division of Hematology/Oncology, Wayne State University, Detroit, Michigan111 G, Oncology, VA Medical Center, Allen Park, MI, 48101===Search for more papers by this authorKenneth J. Pienta M.D., Kenneth J. Pienta M.D. Division of Hematology/Oncology, Division of Hematology/Oncology, Wayne State University, Detroit, MichiganSearch for more papers by this authorBruce G. Redman D.O., Bruce G. Redman D.O. Division of Hematology/Oncology, Division of Hematology/Oncology, Wayne State University, Detroit, MichiganSearch for more papers by this authorGlenn D. Cummings Ph.D., Glenn D. Cummings Ph.D. Section of Biostatistics, Division of Hematology/Oncology, Wayne State University, Detroit, MichiganSearch for more papers by this authorLawrence E. Flaherty M.D., Lawrence E. Flaherty M.D. Division of Hematology/Oncology, Division of Hematology/Oncology, Wayne State University, Detroit, MichiganSearch for more papers by this author Maha H. Hussain M.D., Corresponding Author Maha H. Hussain M.D. Hematology/Oncology, VA Medical Center, Allen Park, Michigan, Division of Hematology/Oncology, Wayne State University, Detroit, Michigan111 G, Oncology, VA Medical Center, Allen Park, MI, 48101===Search for more papers by this authorKenneth J. Pienta M.D., Kenneth J. Pienta M.D. Division of Hematology/Oncology, Division of Hematology/Oncology, Wayne State University, Detroit, MichiganSearch for more papers by this authorBruce G. Redman D.O., Bruce G. Redman D.O. Division of Hematology/Oncology, Division of Hematology/Oncology, Wayne State University, Detroit, MichiganSearch for more papers by this authorGlenn D. Cummings Ph.D., Glenn D. Cummings Ph.D. Section of Biostatistics, Division of Hematology/Oncology, Wayne State University, Detroit, MichiganSearch for more papers by this authorLawrence E. Flaherty M.D., Lawrence E. Flaherty M.D. Division of Hematology/Oncology, Division of Hematology/Oncology, Wayne State University, Detroit, MichiganSearch for more papers by this author First published: 1 July 1994 https://doi.org/10.1002/1097-0142(19940701)74:1 3.0.CO;2-KCitations: 34AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract Background. Hormone-refractory prostate cancer generally remains a chemotherapy-resistant tumor and therefore warrants the continued evaluation of promising agents. Methods. Twenty-two eligible patients with hormone-refractory prostate cancer were treated with oral etoposide at a dosage of 50 mg/m2/day for 21 days in a 28-day cycle. Response was evaluated using standard solid tumor response criteria. Results. There were two partial responses of 6 and 14 months' duration, respectively. Two patients had disease stabilization, one for 6 months and one for 12 months. Median survival was 31 weeks, with an overal 1-year survival of 30%. Reversible alopecia and myelosuppression were the primary toxicities noted. Conclusions. Single-agent oral etoposide has minimal activity in patients with hormone-refractory prostate cancer. References 1 Eisenberger M, Simon R, O'Dwyer P, Wittes RE, Friedman MA. A re-evaluation of non-hormonal cytotoxic chemotherapy for prostate carcinoma. J Clin Oncol 1985; 3: 827–41. 2 Scher HI, Sternberg CN. Chemotherapy of urologic malignancies. Semin Urol 1985; 3: 239–80. 3 Walther PJ, Williams SD, Troner M, Greco FA, Birch R, Einhorn LH, and the Southeastern Cancer Study Group. Phase II study of etoposide for carcinoma of the prostate. Cancer Treat Rep 1986; 70 (6): 771–2. 4 Smart T, Hollander P, Yagoda A. Etoposide in prostatic cancer: experimental studies and phase II trials in patients with bidimensionally measurable disease. Cancer Chem Pharmacol 1986; 18 (1): 24–6. 5 Slevin ML, Clark PI, Joel SP, Malik S, Osborn RJ, Gregory WM, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 1989; 7: 1333–40. 6 Hainsworth JD, Johnson DH, Frazier SR, Greco FA. Chronic daily administration of oral etoposide-A phase I trial. J Clin Oncol 1989; 7: 396–401. 7 Johnson DH, Strupp J, Greco FA, Hande KR, Hainsworth JD. Prolonged administration of oral etoposide in previously treated small cell lung cancer patients [abstract]. Proc Am Soc Clin Oncol 1990; 9: 878. 8 Miller JC, Loehrer PJ, Williams SD. Phase II study of daily oral VP-16 in refractory germ cell tumors [abstract]. Proc Am Soc Clin Oncol 1989; 18: 145. 9 Greco FA, Johnson DH, Hainsworth JD. Chronic daily administration of oral VP-16. Semin Oncol 1990; 17: 71–4. 10 SAS Institute. The life test procedure. SAS/STAT user's guide. Vol. 2. Version 6. 4th ed. Cary, NC: SAS Institute Inc., 1990: 1027–71 11 Crawford ED, Daneshgari F, Majeski SA. Etoposide in the treatment of hormone-refractory advanced carcinoma of the prostate. Sem Oncol 1992; 19 (Suppl 14): 53–7. 12 Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993, 71 (3 Suppl): 1098–1109. 13 Wozniak AJ, Blumenstein BA, Crawford ED, Boileau M, Rivkin SE, Fletcher WS. Cyclophosphamide, methotrexate, and 5-flu-orouracil in the treatment of metastatic prostate cancer: a Southwest Oncology Group Study. Cancer 1993; 71 (12): 3975–8. 14 Petrylak DP, Scher HI, Li Z, Myers CE, Geller NL. Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone refractory prostate cancer treated with single agent chemotherapy. Cancer 1992; 70: 2870–8. 15 Berry WR, Laszlo J, Cox E, Walker A, Paulson D. Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer 1979; 44: 763–75. 16 Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 607–15. Citing Literature Volume74, Issue11 July 1994Pages 100-103 ReferencesRelatedInformation